Study on material basis and pharmacodynamic mechanism of heat-clearing and damp-eliminating Ermiao Powder based on chinmedomics

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200005523

Enrollment

Unknown

Registered

2022-01-10

Start date

2021-12-10

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gouty arthritis

Interventions

Heathy group (no randomization):None

Sanmiao Powder Goup:Sanmiao Powder Granule

Ermiao Powder Goup:Ermiao Powder Granule

Gout patients control group:None

Simiao Powder Goup:Simiao Powder Granule

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Healthy population: (1) The age ranged from 18 to 70 years; (2) The subjects or their family members (guardians) agreed to participate in the study and signed the informed consent. 2. Patients with gouty arthritis: (1) The subjects meet the 2015 ACR/EULAR diagnostic criteria for gouty arthritis; (2) The subjects meet the diagnostic criteria of wet syndrome established by The State Key Laboratory of Dampness Syndrome of Chinese Medicine and are accompanied by redness, swelling, heat and pain of lower limb arthritis; (3) The age ranged from 18 to 70 years; (4) Written informed consent to participate in the study signed by the subjects or their family members (guardians).

Exclusion criteria

Exclusion criteria: 1. Healthy population: (1) Patients with hyperuricemia or gouty arthritis; (2) Patients with serious cardiovascular, brain, lung, liver, kidney, gastrointestinal, hematopoietic system diseases, malignant tumors and mental diseases; (3) Pregnant or lactating women; 2. Patients with gouty arthritis: (1) Patients with severe cardiovascular, brain, lung, liver, kidney, hematopoietic system diseases, malignant tumors and mental diseases; (2) Pregnant or lactating women; (3) Patients with active gastroduodenal ulcer or gastritis caused by long-term use of non steroidal anti-inflammatory drugs; (4) Patients with secondary gout caused by potential diseases or drugs (such as aspirin, cyclosporine, diuretics, etc.)

Design outcomes

Primary

Measure	Time frame
UA;	—

Secondary

Measure	Time frame
visual analogue scale;ESR;Dampness Syndrome evaluation;CRP;the number of the affected joint and gouty tophus;	—

Countries

China

Contacts

Public ContactHuang Runyue

ryhuang@gzucm.edu.cn15889932190

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026